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Abstract
Kidney donation results in reductions in kidney function and lasting perturbations in phos-
phate homeostasis, which may lead to adverse cardiovascular sequelae. However, the
acute effects of kidney donation on bone mineral parameters including regulators of calcium
and phosphate metabolism are unknown. We conducted a prospective observational con-
trolled study to determine the acute effects of kidney donation on mineral metabolism and
skeletal health. Biochemical endpoints were determined before and after donation on days
1, 2 and 3, 6 weeks and 12 months in donors and at baseline, 6 weeks and 12 months
in controls. Baseline characteristic of donors (n = 34) and controls (n = 34) were similar:
age (53±10 vs 50±14 years, p = 0.33), BMI (26.3±2.89 vs 25.9±3.65, p = 0.59), systolic BP
(128±13 vs 130±6 mmHg, p = 0.59), diastolic BP (80±9 vs 81±9 mmHg, p = 0.68) and base-
line GFR (84.4±20.2 vs 83.6±25.2 ml/min/1.73m2, p = 0.89). eGFR reduced from 84.4±20.2
to 52.3±17.5 ml/min/1.73m2 (p<0.001) by day 1 with incomplete recovery by 12 months
(67.7±22.6; p = 0.002). Phosphate increased by day 1 (1.1(0.9–1.2) to 1.3(1.1–1.4) mmol/L,
p <0.001) but declined to 0.8(0.8–1.0) mmol/L (p<0.001) before normalizing by 6 weeks.
Calcium declined on day 1 (p = 0.003) but recovered at 6 weeks or 12 months. PTH and
FGF-23 remained unchanged, but α-Klotho reduced by day 1 (p = 0.001) and remained low
at 6 weeks (p = 0.02) and 1 year (p = 0.04). In this study, we conclude that kidney donation
results in acute disturbances in mineral metabolism characterised by a reduced phosphate
and circulating α-Klotho concentration without acute changes in the phosphaturic hormones
FGF23 and PTH.
Introduction
Mineral and bone disorder (MBD) is a life-limiting complication in patients with Chronic Kid-
ney Disease (CKD). The three component alterations that characterize MBD include
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disturbances in mineral metabolism, osteodystrophy and extraskeletal calcification. Abnor-
malities in mineral metabolism in CKD include the development hyperphosphataemia, eleva-
tions in the phosphatonins fibroblast growth factor (FGF)-23 and parathyroid hormone
(PTH), reduced circulating active 1,25-dihydroxyvitamin D and hypo- or hypercalcaemia [1].
These pertubations become evident even with very mild decrements in glomerular filtration
rate (GFR) [2]. Epidemiological data suggest that mineral disorders such as hyperparathyroid-
ism and hyperphosphataemia are associated with increased morbidity and mortality, notably
from cardiovascular disease (CVD) [3, 4]. In fact, the development of MBD and CVD are
closely linked and understanding this complex relationship is of critical importance given that
CVD remains the leading cause of death in patients with CKD [5–7].
Skeletal disorders in CKD are characterised by alterations of bone morphology and turn-
over that result in an increased fracture risk and may contribute to extraskeletal calcification
[8]. Notably, CKD-MBD is associated with widespread vascular and soft-tissue calcification.
Arterial calcification is closely linked to arterial stiffness [9] and contributes to the excess car-
diovascular mortality observed in patients with renal impairment [10]. Both skeletal health
and extraskeletal mineralization are intricately linked with calcium and phosphate homeosta-
sis, which is predominanlty regulated by vitamin D, PTH, FGF23 and α-klotho. These modula-
tors of bone mineral metabolism are responsive to changes in kidney function, and interact
with each other and with calcium and phosphate concentrations through multiple endocrine
feedback loops. Establishing the primary abnormality arising from a decrement in eGFR and
driving abnormal mineral metabolism is important in order to guide the design of interven-
tions to reduce the cardiovascular and skeletal sequelae of CKD-MBD [1].
Kidney donation represents an excellent model for studying the effects of a decrease in GFR
on MBD, since it allows interrogation of the effect of an acute and isolated GFR reduction of
50% in the absence of significant systemic disease [11, 12] Further, given concerns over the
cardiovascular sequelae of reductions in GFR [13, 14] (and hence the potential for adverse car-
diovascular consequences of kidney donation) and the converse observation of a reduction in
cardiovascular risk through kidney transplantation [15], there is an urgent need to identify the
relationship between early changes in bone mineral metabolism markers and measures of car-
diovascular and skeletal health.
We conducted a prospective, controlled study of living kidney donors and healthy controls
to elucidate the effects of an acute decrement in GFR on biochemical markers of mineral
metabolism, haemodynamic parameters and skeletal health.
Methods
Study design
The KARMA (Effect of Kidney donAtion on bone and mineRal MetAbolism) study was a sin-
gle-center matched prospective cohort study that enrolled patients between May 2012 and
March 2014 at Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation
Trust (CUH), United Kingdom. All kidney transplants were carried out in the UK National
Health Service. The National Health Service is free at the point of care. Donors did not receive
any payments. The KARMA study design is illustrated in Fig 1. All patients undergoing
donor-nephrectomy were invited to participate. Biochemical parameters were determined on
6 occasions in the donor group before and acutely after donation on post-operative days 1–3,
and 6 weeks and 12 months after kidney donation.
The control group was recruited from patients who volunteered to undergo donor-
nephrectomy and were found to be medically suitable but did not proceed for non-medical
reasons, such as a positive cross match or cadeveric transplant for the planned recipient. We
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sought to match control patients in terms of age and gender as far as possible. Patients with
actual or planned pregnancy were excluded. Biochemical parameters were determined at base-
line, 6 weeks and 12 months in the control group.
In both groups, cardiovascular parameters including ambulatory blood pressure and
carotid-femoral pulse wave velocity were recorded. The donor group underwent bone mineral
density (BMD) assessment by DEXA scanning at baseline and after 12 months. Bone density
was determined by DEXA scanning on all kidney donor patients at baseline and 12 months.
BMD assessment was not carried out in the control group.
Laboratory investigations
Blood and urine samples in the immediate post transplant period (day 1 to day 3 after transplanta-
tion) were taken as early morning samples to ensure standardization. Biochemical analysis was
conducted at Addenbrooke’s Hospital clinical laboratory and Cambridge Core Biochemical Assay
Laboratory (CBAL). Creatinine, calcium, inorganic phosphate, albumin & alkaline phosphatase
were analysed on the Siemens Advia 2400 autoanalyser. PTH [normal range 14–72 ng/l] was ana-
lysed using the ADVIA1 Centaur XP Immunoassay system for intact PTH (1–84) The eGFR
was computed using the four-variable Modification of Diet in Renal Disease equation. Serum
FGF-23 levels were analyzed using an ELISA kit detecting the FGF-23 c-terminal (Immutopics;
Cat #60–6100). This assay detects both the intact molecule and large carboxyl terminal fragments
of human FGF-23. Serum α-Klotho levels were analyzed (Immuno-Biological Laboratories Co.,
Ltd., Cat #27998). 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D were analysed by auto-
mated chemiluminescent immunoassay on the Diasorin Liaison XL autoanalyser.
Ethical approval
The study protocol was approved by the NRES Committee East of England–Cambridge EAST
(REC reference 10/H0304/74). All participants provided written informed consent. None of
Fig 1. The KARMA study design.
https://doi.org/10.1371/journal.pone.0235082.g001
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the transplant donors were from a vulnerable population and all donors provided written
informed consent that was freely given.
Kidney donation
Prospective kidney donors were seen on multiple occasions on separate dates in the outpatient
clinic during the screening process and interviewed by a member of the transplant team and a
transplant coordinator. Information about donation was provided in written and verbal form,
with a full description of the procedure, the potential risks and complications and the nature
and duration of the recovery period. Prospective donors were afforded as much time as
required to come to a decision. All donors were living donors and were registered as organ
donors. No organs were obtained from deceased donors. Kidney donation for transplantation
followed a standard local protocol. Nephrectomy was performed by a laparoscopic technique.
Donors received enoxaparin 40mg before surgery, flucloxacillin 1 gram and 100ml 20% man-
nitol intravenously intra-operatively, ibuprofen 200mg three times daily and paracetamol 1
gram 6 hourly as required in the post-operative period, and intravenous fluid as 0.9% Saline as
required. Donors remained nil by mouth on the day of donation, but were allowed an oral diet
from day 1 after donation. The majority of transplant donors were discharged from hospital
on the second or third post-operative day.
Statistical analysis
Data are presented as mean ± SD, median (IQR) according to their distribution. Counts are
presented as frequencies (%). Between-group comparisons were performed using independent
samples T tests or Mann Whitney U-tests as appropriate. Within-subject comparisons were
made using repeated measures ANOVA, or chi-squared for categorical variables. Parameter
estimate, standard error, and 95% confidence interval (CI) were calculated for each variable.
P<0.05 was considered statistically significant. All analyses were conducted using STATA
(version 14).
Results
We enrolled 34 kidney donors and 34 controls between 2012 and 2016 at Addenbrooke’s Hos-
pital, Cambridge.
Clinical characteristics of the study population
Clinical and biochemical parameters between the donor and control populations were similar
at baseline (Table 1). A similar proportion (20/34, 59%) of the donors and controls (16/34,
47%) were male. The mean age of donors was 53±10 years, and did not differ from controls
(50±14 years, p = 0.33). There was no difference in BMI (26.3±2.89 vs 25.9±3.65 kg/m2,
p = 0.59), systolic and diastolic clinic blood pressure (SBP 128±13 vs 130±13mmHg, p = 0.59;
DBP 80±9 vs 81±9 mmHg, p = 0.68) between donors and controls. PWV was also not statisti-
cally different between the donor and control groups at baseline (7.2 (6.8–7.8) vs 6.6 (6.0–7.7)
ms, p = 0.25). Baseline eGFR was similar between donors and controls (84.4±20.2 vs 83.6±25.2
ml/min/1.73m2, p = 0.89). Biochemical and hematologic parameters between groups, includ-
ing phosphate (p = 0.97), PTH (p = 0.74) and hemoglobin (p = 0.19), were not statistically dif-
ferent. Donor patients had marginally higher albumin (41.0 (39–42) vs 39.0 (37–42) mg/l,
p = 0.02) levels than control patients.
PLOS ONE Nephrectomy and mineral metabolism
PLOS ONE | https://doi.org/10.1371/journal.pone.0235082 July 7, 2020 4 / 14
Biochemical parameters
Kidney donation reduced eGFR markedly from 84.4±20.2 to 52.3±17.5 ml/min/1.73m2
(p<0.001) on post-operative day 1 (Table 2; Fig 2A). As expected, eGFR subsequently
increased, but remained lower than baseline 6 weeks (60.0±20.0; p<0.001) and 12 months
(67.7±22.6; p = 0.002) following kidney donation. eGFR was significantly lower in donors
compared to controls at 6 weeks (p<0.001) and 12 months (p<0.001). Laboratory measure-
ments early after kidney donation on post-operative days 1–3 are shown in Table 2 and mid-
term changes at 6 weeks and 12 months are shown in Table 3. We will first describe acute min-
eral changes followed by mid-term changes.
Acutely, albumin-corrected calcium concentration was reduced from 2.3±0.07 to 2.2 ± 0.05
mg/l (p = 0.003) by post-operative days 1 and remained low by post-operative day 3. Serum
phosphate concentrations showed an increase from 1.1 (1.0–1.2) to 1.3 (1.1–1.4) mmol/L
(p<0.001) by day 1 before declining sharply below baseline by day 2 (0.9 (0.8–1.0) p<0.001)
and 3 (0.8 (0.8–0.9), p<0.001)(Fig 2C). The acute changes in phosphate not paralleled by any
statistically significant changes in PTH levels from post-opertive days 1–3. However, these
changes were associated with an increase in the fractional excretion (%) of phosphate from
baseline (7.6±3.60) by day 1 (29.3±61.6, p = 0.04) post-operatively (Fig 3). Fractional excretion
of phosphate reduced but remained elevated above baseline on day 2 (14.7±5.9, p<0.001) and
Table 1. Baseline characteristics.
Variables Control Donor p-value
No. of subjects 34 34 -
Male, n (%) 20 (59) 16 (47) 0.33
Age, years 53±10 50±14 0.33
BMI 25.9±3.65 26.3±2.89 0.59
Systolic BP, mmHg 129.6±12.8 127.9±13.01 0.59
Diastolic BP, mmHg 81.21±9.46 80.3±9.15 0.68
Tobacco:
- Smokers, n (%) 1 (2.9) 1 (2.9) -
- Ex-smokers, n (%) 5 (14.7) 18 (52.9) -
Applanation tonometry:
- PWV, m/s 6.6[6.0, 7.7] 7.2[6.8, 7.8] 0.25
Laboratory:
- eGFR, ml/min/1.73m2 83.6±25.2 84.4±20.2 0.89
- Creatinine, mg/dL 79.5±19.1 81.5±10.9 0.82
- Corrected calcium, mmol/L 2.19[2.13–2.22] 2.23[2.12–2.28] 0.001
- Phosphate, mmol/L 1.1[0.97, 1.15] 1.1[0.95,1.23] 0.97
- Albumin, mg/l 39.0[37,42] 41.0[39,42] 0.02
- PTH, pmol/l 4.4[3.71, 8.5] 4.8[3.39, 5.83] 0.74
- 25-vitamin D, ng/ml 19.6[17.0, 22.7] 21.5[16.2, 24.8] 0.77
- 1,25-vitamin D, ng/ml 44.8 [37.2, 49.2] 49.5[40.8, 56.7] 0.15
- α-Klotho, pg/ml 893.4[739.8, 1051.0] 931.1 [662.7, 1144.6] 0.69
- FGF-23, RU/ml 49.0[28.0, 81.0] 47.7[35.9, 55.8] 0.37
- Alkaline phosphatase, ALP 76.0 [64.0, 101.0] 97.5 [84.0, 111.0] 0.01
- hs-CRP, mg/ml 1.2 [0.50, 1.9] 1.8 [0.86, 2.9] 0.25
- Hemoglobin, g/dl 13.8[12.9,14.1] 13.9[13.2, 14.7] 0.19
Data are presented as mean ± SD, median [interquartile range] or frequencies (%). P-value was obtained by student t-test.
https://doi.org/10.1371/journal.pone.0235082.t001
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day 3 (14.3±6.3, p<0.001) post-operatively. Alkaline phosphatase (ALP) reduced from 97.5
(84.0–111.0) to 79.5 (70.0–88.0) (p<0.001) by day 1 following donation (Fig 2F).
On mid-term follow-up, we found that albumin-corrected calcium concentrations t did not
differ at 6 weeks or 12 months after donation (Fig 2E). Phosphate levels were not statistically
Table 2. Laboratory measurements in the acute period after kidney donation.
Variables Timepoint Control Donor p-value1
- eGFR, ml/min/1.73m2 Baseline 83.6±25.2 84.4±20.2 -
Day 1 - 52.3±17.5 <0.001
Day 2 - 51.9±18.7 <0.001
Day 3 - 58.0±22.4 <0.001
- Creatinine Baseline 79.5±19.1 81.5±10.9 -
Day 1 - 126.1±22.3 <0.001
Day 2 - 128.6±25.7 <0.001
Day 3 - 117.5±26.7 <0.001
- Corrected calcium, mmol/L Baseline 2.25±0.1 2.3±0.07 -
Day 1 - 2.2±0.05 0.003
Day 2 - 2.2±0.06 0.008
Day 3 - 2.2±0.09 0.002
- Phosphate, mmol/L Baseline 1.1[1.0, 1.2] 1.1[0.9,1.2] -
Day 1 - 1.3[1.1, 1.4] <0.001
Day 2 - 0.9[0.8, 1.0] <0.001
Day 3 - 0.8[0.8, 0.9] <0.001
- Alkaline phosphatase Baseline 76.0[64.0, 101.0] 97.5[84.0, 111.0] -
Day 1 - 79.5[70.0, 88.0] <0.001
Day 2 - 80.0[73.0, 92.0] <0.001
Day 3 - 82.0[63.0, 104.0] 0.05
- PTH, pmol/l Baseline 4.4[3.71, 8.5] 4.8[3.4, 5.8] -
Day 1 - 4.0[3.3, 6.5] 0.829
Day 2 - 3.8[2.9, 5.4] 0.250
Day 3 - 4.6[2.7, 5.5] 0.661
- 25-vitamin D, ng/ml Baseline 19.6[17.0, 22.7] 21.5 [16.2, 24.8] -
Day 1 - 30.5[18.0, 53.0 0.19
Day 2 - 36.5[16.0, 49.0] 0.03
Day 3 - 48.0[39.0, 66.0] 0.23
- 1,25-vitamin D, ng/ml Baseline 44.8 [37.2, 49.2] 49.5 [40.8, 56.7] -
Day 1 - 45.5[32.0, 63.0] <0.001
Day 2 - 30.0[14.0, 49.0] <0.001
Day 3 - 38.0[9.0, 57.0] <0.001
- α-Klotho, pg/ml Baseline 893.4[739.8, 1051.0] 931.1 [662.7, 1144.6] -
Day 1 - 677.7 [536.7, 833.9] 0.001
Day 2 - 574.9 [470.0, 757.8] <0.001
Day 3 - 505.0[436.0, 638.4] <0.001
- FGF-23, RU/ml Baseline 49.0[28.0, 81.0] 47.7[35.9, 55.8] -
Day 1 - 51.1[39.2, 72.4] 0.97
Day 2 - 36.1[31.1, 53.1] 0.57
Day 3 - 32.9[28.5, 45.5] 0.75
Data are presented as means ± SD, median [interquartile range] or frequencies (%). P-value was obtained by repeated measures t-test. P-value1: Each P value was
compared to baseline.
https://doi.org/10.1371/journal.pone.0235082.t002
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different compared to baseline at 6 weeks (p = 0.381) or at 1 year (p = 0.115) after donation.
However, PTH levels increased from 4.7 to 5.8 (4.6–8.7) pmol/L (p = 0.018) after 12 months,
but was not statistically different after 6 weeks (Table 3, Fig 2B). There was no significant dif-
ference in fractionale excretion (%) of phosphate at 6 weeks (14.9±24.6, p = 0.09) and 12
months (17.2±30.5, p = 0.07) compared to baseline. ALP levels recovered to near baseline
Fig 2. Changes in biochemical parameters over time. Legend: Changes in biochemical parameters from baseline at days 1, 2 and 3, 6 weeks and 12
months after donation in Donors (blue) and at 6 weeks and 12 months in Controls (red). Donation resulted in a marked and sustained reduction in
eGFR (ml/min/1.73m2) (A), a striking increase followed immediately by a decrease in phosphate (C) despite a late and non significant change in intact
PTH (pmol/l) (B) and no significant change in FGF-23 (RU/ml) (G). Klotho (pg/ml) reduced significantly immediately after donation and remained
below baseline (D). Corrected calcium (mmol/L) reduced (E) in parallel to changes in 1,25-dihydroxyvitamin D (ng/ml) (H). Dashed lines illustrated
mean or median, solid lines represent SD or IQR.
https://doi.org/10.1371/journal.pone.0235082.g002
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(p = 0.247; Table 3; Fig 2) after 6 weeks, but showed a further decline 12 months following kid-
ney donation (p = 0.003).
Changes in FGF-23, vitamin D and Klotho
Acutely, FGF-23 levels were unchanged from baseline (47.7 (35.9–55.8) RU/ml) to day 1 (51.1
(39.2–72.4) RU/ml, p = 0.97), day 2 (36.1 (31.1–53.1) RU/ml, p = 0.57) or day 3 (32.9 (28.5–
45.5) RU/ml, p = 0.75) after kidney donation (Table 3; Fig 2G). Soluble α-klotho decreased
markedly from 931 (662.7–1144.6) at baseline to 677.7 (536.7–833.9) (p = 0.001; Table 3; Fig 2)
by day 1 following kidney donation (Fig 2D). Active vitamin D (1,25-dihydroxyvitamin D3)
concentration decreased significantly by day 1 (p-<0.001; Table 3; Fig 2) and remained low by
post-operative day 3. The concentration of 25-hydroxyvitamin D3 did not change after kidney
donation (Fig 2I).
Table 3. Laboratory measurements mid-term after kidney donation.
Variables Group Baseline 6 weeks 12 months p-value1
- eGFR, ml/min/1.73m2 Controls 83.6±25.2 87.2±25.9 88.6±24.3 0.568//0.416
Donors 84.4±20.2 60.0±20.0 67.7±22.6 <0.001/0.002
p-value2 0.893 <0.001 <0.001
- Creatinine Controls 79.5±19.1 76.5±16.0 73.5±18.9 0.328/0.008
Donors 81.5±10.9 79.9±10.9 112.2±17.1 <0.001/<0.001
p-value2 0.003 <0.001 0.006
- Corr calcium, mmol/L Controls 2.2±0.1 2.2±0.1 2.2±0.1 0.212/0.107
Donors 2.2±0.1 2.3±0.1 2.3±0.1 0.182/0.112
p-value2 0.001 0.005 0.02
- Phosphate, mmol/L Controls 1.1[0.97, 1.2] 1.1[1.0, 1.2] 1.1[1.1,1.2] 0.312/0.405
Donors 1.11[0.95,1.2] 1.0[1.0, 1.13] 1.0[0.9, 1.1] 0.381/0.115
p-value2 0.977 0.06 0.04
- Alkaline phosphatase, IU/L Controls 76.0[64.0, 101.0] 71.0[62.0, 81.0] 64.0[50.5, 76.0] 0.398/0.008
Donors 97.5[84.0, 111.0] 106[89.0, 122.0] 85.0[66.5, 95.0] 0.247/0.003
p-value2 0.010 <0.001 0.005
- PTH, pmol/l Controls 4.4[3.71, 8.5] 4.7[3.9, 6.3] 5.7[4.77, 7.1] 0.569/0.05
Donors 4.77[3.39, 5.8] 5.3[4.1,7.2] 5.8[4.56, 8.7] 0.130/0.018
p-value2 0.739 0.132 0.701
- 25-vitamin D, ng/ml Controls 23.4[20.5, 29.9] 19.5[17.3, 24.7] 23.0[16.55, 28.35] 0.134/0.287
Donors 21.5[16.2, 24.8] 22.2[14.5, 29.8] 25.3[14.9, 28.2] 0.309/0.119
p-value2 0.769 0.449 0.001
- 1,25-vitamin D, ng/ml Controls 41.9[35.3, 46.6] 41.4[35.7, 47.2] 42.4[32.8, 48.9] 0.627/0.985
Donors 49.5[40.8, 56.7] 30.7[27.1, 36.7] 41.7[33.3, 50.0] <0.001/0.016
p-value2 0.148 <0.001 0.294
- α-Klotho, pg/ml Controls 893.4[739.8, 1051.0] 675.1[604.1, 814.7] 821.8[671.8, 1059.6] -/0.345
Donors 931.1 [662.7, 1144.6] 701.6[548.6, 874.0] 721.4[562.5, 956.5] 0.02/0.04
p-value2 0.699 0.176 0.143
- FGF-23, RU/ml Controls 49.0[28.0, 81.0] 48.0[17.0, 72.0] 57.0[30.0, 83.0] 0.379/0.801
Donors 47.7[35.9, 55.8] 60.2[50.9, 81.2] 64.0 [52.5, 83.4] 0.718/0.616
p-value2 0.489 0.188 0.215
Data are presented as means ± SD, median [interquartile range] or frequencies (%). P-value was obtained by student t-test. P-value1: 6 months vs baseline/12 months vs
baseline in each respective group. P-value2: compares controls vs donors at each respective time-point.
https://doi.org/10.1371/journal.pone.0235082.t003
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On mid-term follow-up, we found no change in FGF-23 levels at 6 weeks (48.0 (17.0–72.0)
RU/ml, p = 0.379) or 12 months (57.0 (30.0–83.0), p = 0.616) after kidney donation. α-Klotho
levels remained low after 6 weeks (701.6 (548.6–874.0), p = 0.02) and 1 year (721.4 (562.5–
956.5), p = 0.04) following kidney donation. Active vitamin D levels remained at months
(p<0.001) and at 12 months (p = 0.016) following kidney donation (Fig 2H). There was no
change in inactive vitamin D at 6 months or 12 months follow-up.
Bone density data
No difference in BMD (bone mineral density) was observed after 12 months compared to baseline
at either the lumbar spine (L1 (p = 0.295), L2 (p = 0.717), L3 (p = 0.466) and L4 (p = 0.943)), fem-
oral neck (p = 0.402), shaft (p = 0.510) or total hip region BMD (p = 0.436) (Table 4).
Discussion
Kidney donation results in a predictable and marked decline in kidney function with incom-
plete recovery. We report the acute and medium-term changes in bone mineral metabolism
Fig 3. Fractional Excretion of Phosphate (FEP) in donors. Data are presented as means ± SD. P-value was obtained by student t-test: compared to baseline.
https://doi.org/10.1371/journal.pone.0235082.g003
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after kidney donation compared to a well matched control population. Our data demonstrate
that disturbances in mineral metabolism occur acutely following kidney donation and are
detectable from the first post-operative day.
Unilateral nephrectomy resulted in a mean decline in eGFR of 38% after 24 hours, and
eGFR remained 20% below baseline after 12 months. We found an acute elevation in serum
phosphate (day 1), followed by an immediate and profound decline in phosphate to signifi-
cantly lower than baseline by day 2. This was associated with an increase in fractional excretion
of phosphate (fePO4). It is therefore likely that the acute loss in GFR results in an initial reduc-
tion in phosphate excretion and hyperphosphataemia, which is (over) corrected by a phospha-
turic response. Despite these observations, it is notable that we identified no detectable change
in the phosphaturic factors PTH and FGF23 over the corresponding period. The driver for the
increase in fePO4 is not known.
In patients with CKD, hyperphosphatemia (and abnormal serum calcium levels) are usually
not observed until the GFR declines to< 40mL/min in CKD patients [16]. However, progres-
sive increases in PTH levels and decreasing serum vitamin D levels are seen in milder decre-
ments in kidney function, typically when GFR is< 60ml/min. Our data showing an
immediate increase in serum phosphate (Fig 2C, Fig 4), followed by a reduction in phosphate
despite no acute change in PTH conflicts with a study by Ponte et al. which reported an
increase in PTH 24 hours after donation without any increment in phosphate [17]. Further,
while Ponte et al. reported no change in corrected calcium concentrations, we identified an
immediate reduction in calcium. It is not clear why these two cohorts demonstrate differing
patterns, but it is possible this may have arisen from differing peri-operative management
regimes resulting from hydration, fasting and need for mineral repletion for example. The
acute increment in phosphate and subsequent decline is unlikely to be attributable to the use
of mannitol which is used to preserve living donor kidney preservation. Mannitol has a short
half-life of approximately 20 minutes, and results in an acute increase in urinary phosphate
Table 4. DEXA parameters in donors.
Baseline 12 months p-value
Lumbar spine BMD (g/cm2):
- L1 1.1±0.1 1.1±0.2 0.295
- L2 1.2±0.2 1.2±0.2 0.717
- L3 1.3±0.2 1.2±0.2 0.466
- L4 1.3±0.2 1.3±0.2 0.943
Lumbar spine Z-score
- L1 -0.1±1.3 -0.2±1.4 0.807
- L2 0.0±1.3 0.1±1.4 0.829
- L3 0.7±1.5 0.6±1.5 0.917
- L4 0.7±1.7 0.8±1.9 0.698
Femoral neck BMD (g/cm2) 0.9±0.1 0.9±0.1 0.402
Femoral neck Z-score 0.0±0.9 0.0±0.8 0.992
0.0±0.11
Total BMD (total hip region) 1.0±0.1 0.9±0.1 0.436
Shaft BMD 1.2±0.2 1.2±0.2 0.510
BMD: Bone Mineral Density
Data are presented as means ± SD
1Delta Z-score
P-value was obtained by student t-test: baseline vs 12 months
https://doi.org/10.1371/journal.pone.0235082.t004
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excretion, mediated by PTH, and is therefore directionally opposite to our observations [18,
19]. Given our observation that FGF23 also did not change, the acute reduction in phosphate
appears to be mediated through a PTH-FGF23 independent mechanism. This may be at least
partly attributable to acute reductions in 1,25-dihydroxyvitamin D, resulting in reduced intes-
tinal and renal tubular phosphate absorption.
We observed numerical but non-significant increases in PTH after 6 weeks, but PTH was
no different between donors and controls after 12 months. In contrast, Kasiske et al. observed
significant elevations in PTH after 6 months (for which we do not have a corresponding time
point) and 36 months [20]. The absence of significant increases in PTH in our study may be
explained by sample size (a larger sample size may have resulted in significance after 6 weeks),
but is difficult to interpret given that time points between these studies do not overlap [17, 21].
In contrast to phosphate, we did not record any similarly biphasic changes in any other
measured parameters over the first 72 hours. We also did not identify any change in bone den-
sity within the follow-up period (Table 4). However, we noted progressive decline in circulat-
ing 1,25-dihydroxyvitamin D, corrected calcium, alkaline phosphatase and circulating klotho.
The absence of a change in bone density should be interpreted with caution since bone loss is
slow in this age group and our study was relatively short in duration and not powered to detect
differences in bone density.
We found that Klotho levels fell acutely by day 1 post-operatively and remained lower than
baseline by 12 months following kidney donation. Klotho is produced predominantly by the
kidney, which is thought to be the major source of circulating Klotho [22, 23] Circulating
Klotho is phosphaturic, through direct inhibition of the apical membrane sodium-coupled
phosphate transporter, NaPi-2a [24]. The results of our study challenge existing paradigms in
Fig 4. Individual patient phosphate concentrations.
https://doi.org/10.1371/journal.pone.0235082.g004
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mineral homeostasis; our data provide evidence that hypophosphatemia can develop in the
absence of serum changes in the phosphaturic hormones, PTH and FGF-23 and despite
declining serum Klotho levels. We postulate that the absence of rising FGF-23 levels in the
acute phase following a decline in GFR may help counteract the development of further
hypophosphatemia.
The strengths of the present study is the inclusion of a well-matched control group to com-
prehensively assess the acute changes in markers of bone and mineral metabolism. Participants
were representative of the typical living kidney donor in the United Kingdom, and no partici-
pants were lost to follow-up. The results of the present study should be cautiously interpreted
in light of its limitations. We recognize several limitations that include a relatively modest sam-
ple size and, to date, short follow-up. In the present study, given that the FGF23 assay used
detects both the intact and c-terminal FGF23 fragments, we are unable to infer changes in the
levels of the intact (active) or cleaved (inactive) FGF23 fragments. Additionally, due to current
limitations in the availability of robust assays for assessing circulating Klotho levels, assessment
of Klotho levels must be cautiously interpreted. To give an example of the magnitude of dis-
crepancy between various assays, in one published study comparing a time-resolved fluores-
cence immunoassay (TRF; Cusabio, China) with an ELISA based assay (IBL, Japan), no
correlation was found between the assays [25].
In summary, we identify biphasic acute changes in phosphate, and acute reductions in cir-
culating klotho, 1,25-dihydroxyvitamin D and calcium. Larger studies with longer follow-up
are required to establish the association between these changes and long term outcomes. Fur-
ther physiological studies are required to establish the basis for the acute changes observed
here.
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